Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

• AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry

Toronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic artificial intelligence platform to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Filament"). The engagement will deploy Kala Bio's purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement to acquire Filament's business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.

Strategic Rationale

The engagement of the Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it looks to expand Filament’s regulated psychedelic drug development platform. By deploying Kala Bio’s purpose-built AI agents, Red Light also intends to accelerate and enhance research planning, scenario simulation, and protocol optimization processes associated with advancing PEX010 through Filament’s clinical development pipeline.

PEX010 is Filament's patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others.

Schreibe Deinen Kommentar